Thursday, April 13, 2017 8:41:32 PM
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On April 10, 2017, the Company received a letter of resignation dated April 9, 2017 from Gino Mauriello resigning as a Director. The remaining board member, Mr. De La Garza accepted the resignation.
On April 11, 2017, Mr. De La Garza as the only remaining board member appointed Albert Carlson PhD and Sammy E Davis DrPH to fill the two vacant board seats.
Albert Carlson, PhD, is 57 years of age and is the Company’s Chief Scientific Officer. He has extensive experience in on-time design to delivery while remaining under budget at all levels of engineering. Additionally, he has worked in many areas of engineering and has focused extensive world knowledge, as well as deep algorithmic, set theory, mathematical, and design expertise. Dr. Carlson holds a PhD in Computer Science from the University of Idaho.
Sammy E. Davis DrPH, 70 years of age has documented experience spanning over 20 years in operations, finance, budgeting, financial reporting, revenue cycle management, inventory, payroll, accounts receivable and payable, and information systems in the healthcare industry. He has held numerous managerial positions as a CEO and Administrator. Dr. Davis holds a Doctor of Public Health degree from the University of Texas.
There are no transactions involving the newly appointed Directors that are reportable under Item 404(a) of Regulation S-K for the purposes of this Current Report on Form 8-K.
Recent SDCH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:54:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:48:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:05:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 12:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:57:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:55:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:53:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 08:51:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:15:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/05/2024 01:00:19 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/28/2023 10:25:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/27/2023 10:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:00:16 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/21/2023 02:09:12 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/11/2023 10:01:10 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 12/04/2023 03:58:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:13:59 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 11/03/2023 02:09:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:54:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:52:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM